Drug Sponsors

Report: Big biopharma would rather ‘make than buy’

Wednesday, November 12, 2014 03:21 PM

Global and generic biopharma companies will continue to prefer in-house manufacturing to outsourcing for the most strategic elements of their businesses, according to a report by PharmSource Information Services, a Virginia-based provider of market intelligence for the global contract biopharma industry.

More... »


UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »

CenterWatch

Perrigo to acquire Omega Pharma for $4.5 billion

Friday, November 7, 2014 01:26 PM

Perrigo, a Dublin, Ireland-based global provider of healthcare products, will acquire Omega Pharma, an OTC healthcare company headquartered in Nazareth, Belgium, for $4.5 billion, including a $3.1 billion purchase price plus assumption of $1.4 billion in debt. The transaction will enhance Perrigo's OTC product offering and expand its distribution through Omega's strong established platform. 

More... »

GVK BIO to acquire Vanta Bioscience

Friday, November 7, 2014 01:09 PM

GVK BIO, a Hyderabad, India-based discovery R&D organization, will acquire Vanta Bioscience, a full-service preclinical GLP toxicology and safety assessment CRO operating from Chennai, India.

More... »

MedImmune acquires Definiens, strengthens immuno-oncology capabilities

Wednesday, November 5, 2014 12:55 PM

AstraZeneca’s global biologics R&D arm MedImmune has entered into an agreement to acquire Germany-based Definiens, a privately held company focused on imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of biomarkers in tumor tissue.

More... »

Bristol-Myers Squibb signs option agreement to acquire Galecto Biotech

Wednesday, November 5, 2014 12:50 PM

Bristol-Myers Squibb has entered into an agreement with the exclusive option to acquire Denmark’s Galecto Biotech and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in phase I development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. Total aggregate payments under the agreement have the potential to reach $444 million, which includes the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments.

More... »

AstraZeneca has acquired Almirall’s respiratory business

Wednesday, November 5, 2014 12:45 PM

Almirall, a global company based in Barcelona dedicated to providing valuable medicines through its R&D, agreements and alliances, has completed the transaction to transfer to AstraZeneca the rights to Almirall's respiratory franchise after all closing conditions have been satisfied. AZ now will own the rights for the development and commercialization of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's partnerships, as well as its pipeline of investigational novel therapies.

More... »

PDR, LDM Group merge

Wednesday, November 5, 2014 12:42 PM

PDR Network, a Montvale, N.J.-based provider of drug information and prescriber communications, has merged with LDM Group, a St. Louis, Mo.-based provider of behavior-based patient and consumer health information.  

More... »

Novartis to sell influenza vaccines business to CSL for $275M

Monday, November 3, 2014 02:39 PM

Novartis has agreed to divest its influenza vaccines business to CSL for $275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.

More... »

Five foundations to participate in Cavendish Global Health Impact Forum

Friday, October 31, 2014 02:18 PM

Cavendish Global has selected five foundations to participate in the Cavendish Global Health Impact Forum taking place Nov. 10-13 at Oxford University in the U.K. The selected organizations and the participating representatives include:

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs